European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts)

MeSH terms

• Blood Pressure / drug effects
• Cardiovascular Agents / pharmacology
• Cardiovascular Agents / therapeutic use*
• Cardiovascular Diseases / blood
• Cardiovascular Diseases / diagnosis
• Cardiovascular Diseases / etiology
• Cardiovascular Diseases / genetics
• Cardiovascular Diseases / physiopathology
• Cardiovascular Diseases / prevention & control*
• Diabetes Mellitus / blood
• Diabetes Mellitus / drug therapy
• Dyslipidemias / blood
• Dyslipidemias / complications
• Dyslipidemias / drug therapy
• Europe
• Female
• Genetic Predisposition to Disease
• Guideline Adherence
• Health Promotion*
• Heart Rate / drug effects
• Humans
• Hypertension / complications
• Hypertension / drug therapy
• Hypertension / physiopathology
• Hypoglycemic Agents / therapeutic use*
• Hypolipidemic Agents / therapeutic use*
• Inflammation / blood
• Inflammation / complications
• Kidney Diseases / complications
• Kidney Diseases / therapy
• Life Style
• Lipids / blood
• Male
• Metabolic Syndrome / complications
• Metabolic Syndrome / drug therapy
• Metabolic Syndrome / physiopathology
• Motor Activity
• Nutritional Physiological Phenomena
• Obesity / complications
• Obesity / physiopathology
• Obesity / therapy
• Overweight
• Primary Prevention / standards*
• Risk Assessment
• Risk Factors
• Sex Factors
• Smoking / adverse effects
• Smoking Cessation
• Stress, Psychological / complications
• Stress, Psychological / therapy
• Treatment Outcome